Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned an average recommendation of “Hold” from the twelve brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $19.8750.

Several equities research analysts have recently weighed in on JSPR shares. UBS Group assumed coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They set a “neutral” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Finally, Rodman & Renshaw began coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective on the stock.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $0.69 on Friday. Jasper Therapeutics has a 12 month low of $0.69 and a 12 month high of $7.19. The firm has a market capitalization of $19.25 million, a PE ratio of -0.15 and a beta of 3.20. The business’s fifty day moving average price is $1.28 and its 200 day moving average price is $1.75.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.47. As a group, equities analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP purchased a new stake in Jasper Therapeutics in the fourth quarter valued at $26,000. Panagora Asset Management Inc. purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth about $35,000. Acadian Asset Management LLC acquired a new stake in shares of Jasper Therapeutics during the first quarter worth about $46,000. Voleon Capital Management LP acquired a new stake in shares of Jasper Therapeutics during the third quarter worth about $50,000. Finally, Marex Group plc purchased a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at about $74,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.